Gilead Sciences, Inc. (GILD)

NASDAQ: GILD · IEX Real-Time Price · USD
68.84
0.27 (0.39%)
At close: Jan 25, 2022 4:00 PM
67.25
-1.59 (-2.31%)
After-hours:Jan 25, 2022 7:58 PM EST
Market Cap86.35B
Revenue (ttm)27.48B
Net Income (ttm)7.39B
Shares Out1.25B
EPS (ttm)5.84
PE Ratio11.78
Forward PE9.92
Dividend$2.84 (4.13%)
Ex-Dividend DateDec 14, 2021
Volume9,239,384
Open68.05
Previous Close68.57
Day's Range67.89 - 69.37
52-Week Range61.39 - 74.12
Beta0.36
AnalystsBuy
Price Target77.00 (+11.9%)
Earnings DateFeb 1, 2022

About GILD

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of l...

IndustryBiotechnology
IPO DateJan 22, 1992
CEODaniel O'Day
Employees13,600
Stock ExchangeNASDAQ
Ticker SymbolGILD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 29 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is 77.00, which is an increase of 11.85% from the latest price.

Price Target
$77.00
(11.85% upside)
Analyst Consensus: Buy

News

Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on studies evaluating the co...

6 hours ago - Business Wire

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 hours ago - Zacks Investment Research

Large Cap Pharma, Biotech Stocks Down on Regulatory Updates

Pharma giants like Pfizer (PFE), Merck (MRK) and Eli Lilly (LLY), along with biotech bigwig Regeneron (REGN), are down on regulatory updates.

Other symbols:LLYMRKPFEREGN
13 hours ago - Zacks Investment Research

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $68.57, moving +0.09% from the previous trading session.

1 day ago - Zacks Investment Research

Gilead (GILD) Drug Gets FDA Nod for Non-Hospitalized COVID Patients

Gilead (GILD) gets FDA approval for label expansion of Veklury for the treatment of non-hospitalized patients at high risk for COVID-19 disease progression.

1 day ago - Zacks Investment Research

FDA Approves Gilead's Remdesivir For Non-Hospitalized COVID-19 Patients At High Risk For Disease Progression

The FDA has approved Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) for non-hospitalized adult and adolescent patients at high risk of progression to severe COVID-19.  This approval expands t...

1 day ago - Benzinga

FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease P...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted expedited approval of a supplemental new drug appl...

4 days ago - Business Wire

Gilead announces massive seizure of counterfeit HIV-1 drugs

The biopharmaceutical company Gilead Sciences announced Wednesday a massive web of seizures across several states of "counterfeit and tampered Gilead HIV medication within the U.S. supply chain."

6 days ago - CNN Business

Gilead Alleges Counterfeiting Network Sold Fake HIV Drugs

Gilead Sciences Inc (NASDAQ: GILD) said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of its HIV treatments over the last two ...

6 days ago - Benzinga

Pharma Giants Go After $10 Billion Market With RSV Drugs

GlaxoSmithKline PLC ( GSK , Financial), Pfizer Inc. ( PFE , Financial) and Johnson & Johnson ( JNJ , Financial) should all know about mid-year if the shots they're developing for a common and potentiall...

Other symbols:GSKJNJPFE
1 week ago - GuruFocus

Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2021 financial results will be released on Tuesday, February ...

1 week ago - Business Wire

Gilead Withdraws Use Of Zydelig In Two Forms Of Blood Cancer In US

Gilead Sciences Inc (NASDAQ: GILD) recently notified the FDA of its decision to voluntarily withdraw the use of Zydelig for two types of blood cancer, including follicular lymphoma (FL) and small lympho...

1 week ago - Benzinga

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $71.77, marking a -0.15% move from the previous day.

1 week ago - Zacks Investment Research

3 Pharma Stocks With Especially Juicy Dividends

These drugmakers should have no problems keeping the dividends flowing -- and growing.

Other symbols:ABBVPFE
1 week ago - The Motley Fool

4 Biotech Acquisitions We'd Like to See in 2022

These potential corporate combinations would make a lot of sense.

Other symbols:BMYSGENVRTX
1 week ago - The Motley Fool

Gilead (GILD) Partners With Merck for Keytruda in NSCLC Study

Gilead (GILD) and Merck collaborate to evaluate the former's breast cancer drug in combination with the latter's blockbuster drug Keytruda for NSCLC study.

Other symbols:MRK
2 weeks ago - Zacks Investment Research

Gilead CEO: Oral version of Covid drug Remdesivir in early testing

Gilead CEO Daniel O'Day sits down with CNBC's Meg Tirrell and the 'Squawk on the Street' team to discuss the company's Covid-19 antiviral, Remdesivir.

2 weeks ago - CNBC Television

Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in Firs...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into two clinical trial collaboration and supply agreements with Merck (known as MSD outside of ...

2 weeks ago - Business Wire

7 Safe Stocks for Your Retirement

In a dynamic market like the one we're in now, it's important to buy safe stocks that will build your nest egg in the years to come. The post 7 Safe Stocks for Your Retirement appeared first on Investor...

Other symbols:BKEOBNKSCVLSTLDVVVMLI
2 weeks ago - InvestorPlace

7 Pharmaceutical Stocks That Could Make You Rich

These seven pharmaceutical stocks could create lucrative opportunities in the new year The post 7 Pharmaceutical Stocks That Could Make You Rich appeared first on InvestorPlace. More From InvestorPlace ...

Other symbols:AMGNBMYLLYNVCRUTHRXPH
2 weeks ago - InvestorPlace

Why Gilead (GILD) is Poised to Beat Earnings Estimates Again

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

2 weeks ago - Zacks Investment Research

2 Top Dividend Stocks That Are Yielding More Than 3%

They pay more than double the S&P 500 average.

Other symbols:KHC
2 weeks ago - The Motley Fool

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $73.64, marking a +0.92% move from the previous day.

3 weeks ago - Zacks Investment Research

Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength

3 Biopharma Stocks Displaying Relative Strength Heading Into 2022

Other symbols:CDMOREGN
3 weeks ago - Zacks Investment Research

GILD or VIR: Which Is the Better Value Stock Right Now?

GILD vs. VIR: Which Stock Is the Better Value Option?

3 weeks ago - Zacks Investment Research